Paper39574178
Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.
Liu S and 9 others. Mol Cancer, 2024. Cited by 223 papers, by iCite.
Cite this record
ConductScience Library. Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer. Papers, record 39574178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39574178
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Neoplasm Metastasis | Major topic |
| Humans | |
| Female | |
| Animals | |
| Tumor Microenvironment | |
| Cellular Reprogramming | |
| Antineoplastic Agents | |
| Energy Metabolism | |
| Metabolic Reprogramming |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2023-KYYWF-0202 | Harbin Medical University | PubMed |
Source PubMed
References680
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38169800 | Metabolic reprogramming in the tumor microenvironment: unleashing T cell stemness for enhanced cancer immunotherapy. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/38169800 | PubMed |
| 2 | 31723000 | Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. | Cancer Res | 2020 | https://conductscience.org/library/papers/31723000 | PubMed |
| 3 | 30143015 | Association of tamoxifen resistance and lipid reprogramming in breast cancer. | BMC Cancer | 2018 | https://conductscience.org/library/papers/30143015 | PubMed |
| 4 | 17255361 | Inhibitory effect of tumor cell-derived lactic acid on human T cells. | Blood | 2007 | https://conductscience.org/library/papers/17255361 | PubMed |
| 5 | 36121176 | Chrysin targets myeloid-derived suppressor cells and enhances tumour response to anti-PD-1 immunotherapy. | Clin Transl Med | 2022 | https://conductscience.org/library/papers/36121176 | PubMed |
| 6 | 37996538 | Eph receptors and ephrins in cancer progression. | Nat Rev Cancer | 2024 | https://conductscience.org/library/papers/37996538 | PubMed |
| 7 | 37133969 | Tumor-Specific Peroxynitrite Overproduction Disrupts Metabolic Homeostasis for Sensitizing Melanoma Immunotherapy. | Adv Mater | 2023 | https://conductscience.org/library/papers/37133969 | PubMed |
| 8 | 31629410 | Tumor-associated macrophages: an accomplice in solid tumor progression. | J Biomed Sci | 2019 | https://conductscience.org/library/papers/31629410 | PubMed |
| 9 | 30914826 | Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. | Nat Rev Clin Oncol | 2019 | https://conductscience.org/library/papers/30914826 | PubMed |
| 10 | 12142961 | Obesity and immunocompetence. | Eur J Clin Nutr | 2002 | https://conductscience.org/library/papers/12142961 | PubMed |
| 11 | 32066951 | Distinct microbial and immune niches of the human colon. | Nat Immunol | 2020 | https://conductscience.org/library/papers/32066951 | PubMed |
| 12 | 37242217 | Long-Term Effects of a Ketogenic Diet for Cancer. | Nutrients | 2023 | https://conductscience.org/library/papers/37242217 | PubMed |
| 13 | 24812208 | The cellular and molecular origin of tumor-associated macrophages. | Science | 2014 | https://conductscience.org/library/papers/24812208 | PubMed |
| 14 | 33546704 | The cancer metabolic reprogramming and immune response. | Mol Cancer | 2021 | https://conductscience.org/library/papers/33546704 | PubMed |
| 15 | 33669775 | Therapeutic Targeting of the Tumour Microenvironment in Metastatic Colorectal Cancer. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33669775 | PubMed |
| 16 | 38507720 | A Subpopulation of Luminal Progenitors Secretes Pleiotrophin to Promote Angiogenesis and Metastasis in Inflammatory Breast Cancer. | Cancer Res | 2024 | https://conductscience.org/library/papers/38507720 | PubMed |
| 17 | 30262472 | Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. | Science | 2018 | https://conductscience.org/library/papers/30262472 | PubMed |
| 18 | 31852848 | Regulatory T cells use arginase 2 to enhance their metabolic fitness in tissues. | JCI Insight | 2019 | https://conductscience.org/library/papers/31852848 | PubMed |
| 19 | 33408816 | Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent manner. | J Extracell Vesicles | 2020 | https://conductscience.org/library/papers/33408816 | PubMed |
| 20 | 30051890 | Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. | Nature | 2018 | https://conductscience.org/library/papers/30051890 | PubMed |
Cited by175
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 223 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42988793 | SWI/SNF subunit SMARCD1 deficiency promotes clear cell renal cell carcinoma progression via mitochondrial reprogramming. | Nat Commun | 2026 | https://conductscience.org/library/papers/42988793 | PubMed |
| 42964571 | Breast cancer adaptation to oxygen stress: mechanisms of tumor survival, progression, and therapeutic resistance. | Oncol Rev | 2026 | https://conductscience.org/library/papers/42964571 | PubMed |
| 42964275 | Addressing unmet clinical needs in treatment-resistant breast cancer: expanding the diagnostic-prognostic landscape through next-generation inflammatory signatures. | Oncol Rev | 2026 | https://conductscience.org/library/papers/42964275 | PubMed |
| 42939881 | Therapeutic Redox Reprogramming in Breast Cancer: From Antioxidant Modulation to Precision Nanomedicine. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/42939881 | PubMed |
| 42910173 | Identification of Immuno-Diagnostic and Therapeutic Markers in Tumors and Inflammatory Diseases Based on Single-Cell and Machine Learning Methods. | Hum Mutat | 2026 | https://conductscience.org/library/papers/42910173 | PubMed |
| 42874536 | NR3C2 suppresses triple-negative breast cancer progression by regulating mitochondrial ROS homeostasis via NDUFB3. | Transl Oncol | 2026 | https://conductscience.org/library/papers/42874536 | PubMed |
| 42855711 | RNA N4-acetylcytidine modification in health and cancer: molecular mechanisms, cellular plasticity, and therapeutic opportunities. | Biomark Res | 2026 | https://conductscience.org/library/papers/42855711 | PubMed |
| 42827658 | Cancer Cell Metastasis: From Molecular Mechanisms to Therapeutic Strategies. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42827658 | PubMed |
| 42798757 | Lipid metabolism reprogramming: key mechanism of breast cancer endocrine therapy resistance. | Front Oncol | 2026 | https://conductscience.org/library/papers/42798757 | PubMed |
| 42789583 | Integrative computational analysis of public fecal lipidomics and transcriptomics datasets suggests a candidate association between the COX-2 pathway and CE(20:4) in colorectal adenoma-carcinoma progression. | PLoS One | 2026 | https://conductscience.org/library/papers/42789583 | PubMed |
| 42780345 | The mechanism of breast cancer stem cells and tumor microenvironment promoting radioresistance in breast cancer and its intervention strategies. | Front Immunol | 2026 | https://conductscience.org/library/papers/42780345 | PubMed |
| 42778549 | Heterogeneity in cancer: molecular mechanisms and therapeutic strategies. | Signal Transduct Target Ther | 2026 | https://conductscience.org/library/papers/42778549 | PubMed |
| 42776318 | SUCLG2 contributes to platinum resistance in lung adenocarcinoma through enhancing succinylation of GAC and glutamine metabolism. | Apoptosis | 2026 | https://conductscience.org/library/papers/42776318 | PubMed |
| 42758515 | Pyrroline-5-carboxylate reductase 1 interacts with Nudix hydrolase 5 to drive bladder cancer malignant progression via activation of the APOE/JAK2/STAT3 signalling axis. | Clin Transl Med | 2026 | https://conductscience.org/library/papers/42758515 | PubMed |
| 42756460 | Immune evasion driven by lipid metabolic reprogramming in endocrine-resistant HR+ breast cancer: antigen presentation defects and T-cell dysfunction. | Front Immunol | 2026 | https://conductscience.org/library/papers/42756460 | PubMed |
| 42746350 | Microbiota-driven metabolic-immune crosstalk in breast cancer. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42746350 | PubMed |
| 42733578 | ENO1 as a potential tumor prognostic marker promotes the proliferation, invasion, and metastasis of breast cancer cells. | Genes Dis | 2027 | https://conductscience.org/library/papers/42733578 | PubMed |
| 42712410 | Therapeutic potential and molecular mechanisms of citrus flavonoids in hepatocellular carcinoma. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42712410 | PubMed |
| 42694955 | Targeting Folate Receptors for the Detection and Selective Treatment of Cancer: Advanced Precision Oncology in Practice. | Int J Biol Sci | 2026 | https://conductscience.org/library/papers/42694955 | PubMed |
| 42657117 | Glycolytic reprogramming in precancerous lesions of gastric cancer progression: pathogenesis and therapeutic potential. | Front Oncol | 2026 | https://conductscience.org/library/papers/42657117 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39574178
GET https://conductscience.org/api/papers/v1/39574178/references?page=2